No Data
No Data
IO Biotech to Present at Jefferies Global Healthcare Conference
A webcast replay of the presentation will be available from the Investors section of the Company's website at for 90 days.
HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating
HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating.
IO Biotech Is Maintained at Buy by HC Wainwright & Co.
IO Biotech Is Maintained at Buy by HC Wainwright & Co.
IO Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 775.91% HC Wainwright & Co. $8 → $12 Maintains Buy 03/06/2024 483.94% HC Wainwright & Co. → $8
Optimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data Timeline
Express News | IO Biotech, Inc. : H.c. Wainwright Raises Target Price to $12 From $8
No Data